We propose that if chronic low-grade inflammation is detected through follow-up CRP measurements and is treated among elderly individuals who are ApoE4 carriers, the onset of AD can be delayed or even prevented, since studies have reported that delaying onset by 5 years can reduce the risk for AD by nearly 50%.25 This evidence concerns the gene CRP and Alzheimer disease.